AstraZeneca and two partners plan a trial testing two drugs for breast cancer
Summit Therapeutics announced a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab in combination with Datroway for multiple solid tumor types, beginning with a Phase III study in first-line triple-negative breast cancer. Each company will contribute their respective therapies and share trial costs, while retaining separate development and commercial rights. This partnership aims to leverage ivonescimab's potential as a next-generation immunotherapy and Datroway's TROP2-directed ADC capabilities to improve patient outcomes.
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
Novartis has secured an exclusive worldwide license for Abogen’s Abo2203 and options for other RNA-platform programs, with a deal potentially worth up to $7.2 billion including a $575 million upfront payment. Separately, AstraZeneca and Daiichi Sankyo are collaborating with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across various cancer types, starting with a Phase III trial in triple-negative breast cancer. These agreements reflect a continued strong year for pharmaceutical M&A, as companies expand their reach in autoimmune diseases and oncology.
Summit Therapeutics plans Phase III Datroway breast cancer trial
Summit Therapeutics, AstraZeneca, and Daiichi Sankyo are collaborating on a planned Phase III breast cancer study, testing ivonescimab alongside Datroway. The collaboration follows AstraZeneca's US$2 billion investment in Summit, aimed at supporting combination studies. The trial will initially focus on first-line triple-negative breast cancer and lung cancer, with all three companies sharing costs and retaining rights to their respective medicines.
Summit Therapeutics Stock Climbs Wednesday: What's Happening?
Summit Therapeutics (NASDAQ: SMMT) shares rose Wednesday after the company announced a $2 billion strategic equity investment from AstraZeneca. This investment, in newly issued convertible preferred shares, will accelerate the clinical development of ivonescimab, Summit's investigational bispecific antibody. Additionally, the companies will collaborate on evaluating ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers.
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
AstraZeneca has invested $2 billion in Summit Therapeutics, acquiring preferred stock that converts at $18.36 per share, significantly higher than Summit's current market trading price of $16.39. This investment injects substantial cash into Summit, reducing dilution risk ahead of key clinical trial readouts and an FDA decision for its drug ivonescimab in late 2026. Despite AstraZeneca's confidence, reflected in the premium paid, Wall Street remains cautious, awaiting the HARMONi-3 trial data and the FDA's decision to determine ivonescimab's true value.
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
AstraZeneca invested $2 billion in Summit Therapeutics through preferred stock, converting at $18.36 per share, a price higher than Summit's current market trading price of $16.39. This investment significantly boosts Summit's cash reserves to $2.5 billion, mitigating dilution risks ahead of key regulatory decisions and trial readouts for its drug, ivonescimab. Despite AstraZeneca's vote of confidence, the market remains cautious, with the stock trading below the conversion price, awaiting critical FDA approval and HARMONi-3 trial data by the end of 2026.
AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
AstraZeneca is making a $2 billion equity investment in Summit Therapeutics, signaling a research collaboration focused on combining drugs for gastrointestinal cancers. The deal highlights AstraZeneca's interest in ivonescimab, Summit's bispecific antibody, and its potential in combination with AstraZeneca's own antibody-drug conjugates (ADCs) to overcome drug resistance in cancer treatment. This collaboration underscores a growing trend in the pharmaceutical industry to explore novel drug pairings for enhanced oncology outcomes.
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer
AstraZeneca has announced a strategic equity investment of $2 billion in Summit Therapeutics and a clinical collaboration to advance its leading antibody drug conjugate (ADC) combination strategy in cancer. This partnership will focus on evaluating ivonescimab, a bispecific antibody, with ADCs, including Summit's sonesitatug vedotin (Sone-Ve), across various tumor types, particularly in gastrointestinal cancers. The collaboration aims to broaden AstraZeneca's ADC portfolio and develop new treatment regimens by combining immunotherapies with ADCs.
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
This article details two significant partnerships in the pharmaceutical industry: Novo Nordisk's exclusive license agreement with Hengrui Pharma for the GLP-1/GIP dual agonist HRS-1596, valued at up to $2.6 billion, and AstraZeneca's $2 billion investment in Summit Therapeutics. AstraZeneca's collaboration with Summit aims to advance the development of ivonescimab in combination with antibody-drug conjugates for various cancer types, expanding its oncology pipeline. Both deals highlight strategic moves by major pharmaceutical companies to enhance their portfolios in metabolic diseases and oncology.
Summit Therapeutics Stock Jumps On $2B AstraZeneca Deal
Summit Therapeutics (SMMT) stock jumped over 21% following a $2 billion investment from AstraZeneca and a broad collaboration on ivonescimab, Summit's lead oncology asset. This deal, involving convertible preferred stock at a premium, validates ivonescimab's potential, especially after strong Phase III data in NSCLC and biliary tract cancer. The partnership reduces funding and execution risks for Summit, with a key PDUFA date set for November 14, 2026, driving significant market interest and a bullish analyst upgrade.
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
AstraZeneca has agreed to invest $2 billion in Summit Therapeutics to advance the development of ivonescimab in combination with antibody-drug conjugates across various tumor types. The companies have also initiated a clinical collaboration to evaluate sonesitatug vedotin (Sone-Ve) with ivonescimab for gastrointestinal cancers. This investment follows earlier speculation and comes as Summit Therapeutics' ivonescimab has shown significant survival benefits in lung cancer trials, addressing the company's need for financing.
Summit Therapeutics Stock Rises 7% After AstraZeneca Strategic Investment
Summit Therapeutics (SMMT) stock rose 6.52% following an announcement that AstraZeneca will make a $2.0 billion strategic equity investment in the company. This investment will facilitate collaboration on clinical studies for ivonescimab with other cancer medicines. The transaction is expected to close by the end of the current week.
Summit Therapeutics agrees to US$2B AstraZeneca equity investment
Summit Therapeutics announced a US$2 billion equity investment from AstraZeneca, where AstraZeneca will purchase convertible preferred shares, funding Summit's cancer drug development. This investment gives AstraZeneca approximately 12% interest in Summit's common shares and aims to accelerate the development of ivonescimab in combination with antibody drug conjugates. A separate clinical collaboration agreement covers trials of ivonescimab with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers.
Summit Therapeutics Stock Surges After AstraZeneca Reveals $2 Billion Investment
Summit Therapeutics (SMMT) saw its stock surge by approximately 15% in after-hours trading following an announcement from AstraZeneca (AZN). AstraZeneca revealed a $2 billion investment in Summit Therapeutics, a cancer-drug developer, coupled with an agreement to collaborate on the development of experimental cancer treatments.
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Summit Therapeutics announced that data from the Phase III HARMONi-GI1 trial, conducted in China by Akeso, will be presented at the ESMO 2026 Presidential Symposium. The study evaluates ivonescimab plus chemotherapy against durvalumab plus chemotherapy for advanced biliary tract cancer, demonstrating statistically significant improvements in overall survival, progression-free survival, and objective response rate for the ivonescimab-based regimen. Ivonescimab, a novel bispecific antibody, is already approved in China for non-small cell lung cancer and is undergoing multiple global Phase III trials.
Summit Therapeutics Presents Updated Overall Survival Data for Ivonescimab in EGFR-Mutated NSCLC
Summit Therapeutics presented updated overall survival (OS) data for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC) from its HARMONi Phase III trial at the IASLC World Conference on Lung Cancer. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is being tested in patients who progressed on a third-generation EGFR TKI. While progression-free survival (PFS) improvements have been reported, the full OS dataset is crucial for determining regulatory submission viability and will be key to understanding whether the OS benefit is persuasive or requires longer follow-up.
Summit Therapeutics Shares Rise After Upgrade From Jefferies
Summit Therapeutics' shares increased after Jefferies upgraded the stock and revised its price target. This upgrade comes amidst several recent positive developments for Summit Therapeutics, including positive topline results from a Phase III study for ivonescimab in biliary tract cancer and China approval for ivonescimab in NSCLC. The biopharmaceutical company is focused on developing patient-friendly medicinal therapies.
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy
Summit Therapeutics (SMMT) shares rose 5.8% in premarket trading after Jefferies upgraded the stock to Buy from Hold and increased its price target to $25 from $15. The upgrade is based on anticipated positive progression-free survival data from the company's H3 study for ivonescimab, expected later in 2026, and the potential for overall survival benefits in 2027. Jefferies analysts are confident in ivonescimab's efficacy, citing previous positive results and its first-in-class positioning.
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Summit Therapeutics (SMMT) experienced a 28.19% share price surge following positive results from clinical trials for its bispecific antibody, ivonescimab. Its partner, Akeso Inc., reported significant overall survival improvements in non-small cell lung cancer patients, as well as superiority in treating advanced biliary tract cancer when combined with chemotherapy. These results strengthen the potential for ivonescimab across various cancer indications, though regulatory approval and commercial success are not yet guaranteed.
Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
Summit Therapeutics (SMMT) shares rose after Bernstein SocGen upgraded the biotechnology company from Underperform to Market Perform, raising its price target to $11.90. The upgrade reflects a more appropriate valuation of ivonescimab, the company's late-stage drug candidate, acknowledging the recent reset in its share price. Despite reservations about ivonescimab's potential to replace Keytruda broadly, the firm noted positive broader market conditions and ongoing regulatory review as supportive factors.
HARMONi-GI1 Marks a Major Milestone for Ivonescimab in BTC – Summit Therapeutics
Summit Therapeutics announced that its investigational therapy, Ivonescimab, in combination with chemotherapy, demonstrated a statistically significant overall survival benefit compared to durvalumab plus chemotherapy in a Phase III trial (HARMONi-GI1) for first-line advanced Biliary Tract Cancer (BTC). This trial, conducted by Akeso in China, is the first known Phase III study in advanced BTC to show superiority over an anti-PD-(L)1 combination and represents the first Phase III Ivonescimab readout beyond NSCLC. Ivonescimab is currently approved only by China's NMPA.
Summit Therapeutics (SMMT) Gains from Positive Phase III Trial Results Amid High Price-to-Sales Valuation
Summit Therapeutics (SMMT) recently announced positive topline results from its Phase III HARMONi-GI1 trial for an advanced biliary tract cancer treatment, which was conducted in collaboration with Akeso. Despite a high Price-to-Sales ratio and ongoing unprofitability, the market anticipates substantial future growth driven by its promising clinical pipeline. The company's GF Score is low at 30/100, but significant insider purchases indicate strong internal confidence.
Summit Therapeutics (NASDAQ:SMMT) Clinical Pathway Gains Fresh Attention
Summit Therapeutics (NASDAQ:SMMT), a clinical-stage biotechnology company, is gaining renewed attention due to updates on its development pipeline and market activities. The company focuses on precision medicines, particularly its leading oncology candidate, ivonescimab, and also has a diversified research approach including infectious diseases. Its future direction is closely tied to clinical progress, regulatory developments, and expanding its research programs, such as evaluating ivonescimab across multiple cancer types.
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright
HC Wainwright has reissued a "Neutral" rating for Summit Therapeutics (NASDAQ:SMMT), aligning with the analyst consensus of "Hold" and an average target price of $24.25. The company's shares are trading near their 52-week low at $12.63, and it reported a quarterly EPS of ($0.28), slightly below estimates. Notably, corporate insiders have significantly increased their holdings, purchasing 7.87 million shares valued at approximately $103.6 million in the last 90 days.
Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year Low - Here's Why
Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss of $0.28 per share. Despite the stock's decline, company insiders have shown strong confidence, purchasing 7.87 million shares worth about $103.6 million in the last quarter, bringing their collective ownership to 83.5%.
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT
Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past three months. The company's stock opened down 7.3% at $14.00, and analysts currently have a consensus "Hold" rating with a target price of $24.25, following a missed EPS estimate.
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside
Summit Therapeutics Inc.'s average 12-month price target has been lowered to $28.34 from $29.52 by 14 analysts, yet this new target still suggests an 88% upside from its Aug. 11 closing price. The consensus rating for the stock remains a "Buy" among 18 analysts.
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab
Summit Therapeutics (SMMT) shares rose after China's National Medical Products Administration approved a label expansion for its bispecific antibody ivonescimab, allowing its first-line use with chemotherapy for advanced squamous non-small cell lung cancer. Despite an extremely high price-to-sales ratio and ongoing losses, insider purchases totaling $103.6 million signal strong confidence from those closest to the company. The company's GF Score™ is a low 27/100, reflecting significant challenges in profitability and growth, even with moderate financial strength.
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
Summit Therapeutics announced that its partner Akeso has received approval in China for ivonescimab for use in squamous non-small cell lung cancer (NSCLC). This approval marks a significant milestone for the bispecific antibody, which combines immunotherapy and anti-angiogenesis effects. Ivonescimab is also being developed by Summit Therapeutics in multiple Phase III clinical trials for NSCLC and other solid tumor settings.
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners
Leerink Partners upgraded Summit Therapeutics (NASDAQ:SMMT) from "underperform" to "market perform" with a $13 price target. The company currently holds an average "Hold" rating from analysts with an average price target of $24.25, and recently reported quarterly EPS of -$0.28, missing estimates. Insider buying activity has been significant, with the CEO and CFO purchasing large quantities of shares, leading to insiders owning 83.5% of the company.
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?
Summit Therapeutics (SMMT) has initiated a new Phase II/III trial (HARMONi-GU1) for its drug ivonescimab in first-line bladder cancer, broadening its potential applications beyond lung cancer. While this reinforces the drug's long-term multi-tumor ambition, the near-term investment focus remains on the FDA's decision for ivonescimab in EGFR-mutant NSCLC, expected by November 14, 2026. The trial adds to the company's R&D spending while Summit remains loss-making.
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?
Summit Therapeutics (SMMT) has broadened its ivonescimab program by initiating a Phase II/III trial for first-line bladder cancer, adding to its growing list of target tumors. While this reinforces the long-term potential of ivonescimab, the near-term investment focus remains on the FDA's decision for EGFR-mutant NSCLC, with a PDUFA date of November 14, 2026. The company remains loss-making, and analysts express caution regarding increased R&D spending and the need for clear differentiation to achieve commercial success.
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics
H.C. Wainwright has reiterated a Neutral rating on Summit Therapeutics (NASDAQ:SMMT), noting the company's stock has declined significantly over the past year. The firm highlighted Merck & Co.'s strategy for KEYTRUDA, which impacts the competitive landscape for Summit's drug candidate, ivonescimab. Upcoming catalysts for Summit include HARMONi-3 trial results and a PDUFA date in late 2026.
Summit expands ivonescimab's challenge to Keytruda into bladder cancer
Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims to establish ivonescimab, a PD-1/VEGF bispecific antibody, in additional PD-1-dominated oncology indications, leveraging its mechanism that targets immune evasion and angiogenesis.
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration. Despite significant R&D spending and no current revenue, the drug's broad clinical activity across multiple tumor types suggests strong future revenue potential, although key risks such as trial failures remain.
Summit Therapeutics Launches HARMONi-GU1 Trial for Ivonescimab in Bladder Cancer
Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, aiming to generate registrational data for ivonescimab's application in new tumor types, building on promising earlier results in colorectal cancer.
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study
Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, aiming to enroll approximately 800 patients. The study expands ivonescimab's development program, which now includes 16 Phase III clinical trials across various tumor types, complementing a Biologics License Application for NSCLC with an FDA PDUFA goal date of November 14, 2026.
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Summit Therapeutics has announced the expansion of its ivonescimab global development program with the initiation of the Phase II/III HARMONi-GU1 study for first-line bladder cancer. This trial will evaluate ivonescimab alongside enfortumab vedotin against the current standard of care, pembrolizumab plus enfortumab vedotin, in patients with previously untreated locally advanced or metastatic urothelial carcinoma. This adds to the existing 15 Phase III ivonescimab studies across various tumor types, aiming to address significant unmet needs in bladder cancer treatment.
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside
Summit Therapeutics Inc. (SMMT) presents a compelling opportunity in the biotechnology sector, with analysts projecting a potential upside of 117.69% based on an average target price of $28.34. The company, focused on innovative biopharmaceuticals like ivonescimab for cancer treatment, is currently in phase III clinical trials. Despite facing financial challenges common to biopharmaceutical companies at this stage, technical indicators suggest the stock may be oversold, potentially offering a buying opportunity for risk-tolerant investors interested in long-term growth.
Lightning Round: Summit Therapeutics is a great spec, says Jim Cramer
Jim Cramer, host of "Mad Money," offered his insights on several stocks during a Lightning Round segment. He specifically highlighted
SMMT|Summit Therapeutics Inc|Price:13.030|Chg%:-0.410
This article provides a comprehensive stock analysis of Summit Therapeutics Inc (SMMT) from TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fairly valued stock, despite recent weak market performance. The analysis also details analyst ratings, institutional ownership, and key strengths like high profit growth and its lead development candidate, ivonescimab.
Summit Therapeutics upgraded to Hold as FDA reviews ivonescimab approval, decision expected by Nov 2026.
Summit Therapeutics has been upgraded from Sell to Hold due to the FDA's ongoing review of ivonescimab, with a decision anticipated by November 14, 2026. While the HARMONI study showed statistically significant progression-free survival, overall survival only presented a favorable trend. The company faces stiff competition in the PD-1 therapy market, and investors are awaiting further data and clarity on its competitive standing.
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed?
Summit Therapeutics experienced a 13.2% stock drop following various updates, including a smaller net loss in Q2 2026, a US$380 million equity offering, and crucial overall survival data from its Phase III HARMONi trial for ivonescimab. The company also announced a new collaboration with Arcus Biosciences for a kidney cancer trial. These developments, particularly the encouraging HARMONi data, reinforce ivonescimab's central role in Summit's strategy, though regulatory approval risk remains significant.
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed?
Summit Therapeutics (SMMT) recently announced a reduced net loss, a US$380 million equity offering, and updated overall survival data from its HARMONi trial for ivonescimab, alongside a new kidney cancer trial collaboration. The updated HARMONi data and expanded clinical focus reinforce ivonescimab's central role in Summit's strategy, despite regulatory risks associated with FDA approval and the need for significant revenue and earnings growth to meet analyst projections. The article explores how these developments impact the investment narrative, particularly concerning the upcoming PDUFA decision for ivonescimab.
Summit Therapeutics Inc (SMMT) Institutional Confidence
Summit Therapeutics Inc (SMMT) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 11.68% quarter-over-quarter, now standing at 15.81%. Steven Cohen is the largest institutional shareholder, holding 856.57K shares, despite a slight decrease in his holdings.
Summit Therapeutics stock hits 52-week low at 12.52 USD
Summit Therapeutics stock has fallen to a 52-week low of $12.52, down nearly 60% from its high, with analysts revising earnings estimates downward. Despite this, an InvestingPro analysis suggests the stock may be undervalued. The company recently reported a significant net loss and mixed analyst ratings, with some maintaining a Buy rating while others lowered price targets due to trial timing concerns.
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab
Summit Therapeutics announced its Q2 2026 financial results and significant clinical advancements for ivonescimab. Key highlights include consistent overall survival in both Western and Asian patients for EGFRm NSCLC post-TKI, and a statistically significant overall survival benefit for ivonescimab plus chemotherapy in 1L Squamous NSCLC from the HARMONi-6 trial conducted in China. The company also reported closing the quarter with $690.7 million in cash and investments.
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com
Summit Therapeutics (SMMT) stock has dropped to a 52-week low of $12.52, down nearly 60% from its high, with analysts revising earnings estimates downward. Despite this, InvestingPro suggests the stock may be undervalued. The company recently reported a Q2 net loss of $216 million, missing analyst expectations, while analysts reiterated Overweight/Buy ratings but lowered price targets due to concerns about the HARMONi-3 trial timing.
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) related to alleged self-dealing. The firm is encouraging long-term SMMT stockholders to contact them for a free consultation as they may be entitled to damages and corporate governance reforms. Kuehn Law covers all case costs and does not charge its investor clients.
Summit Therapeutics officers investigated for possible shareholder duty breaches and self-dealing.
Kuehn Law, PLLC is investigating officers and directors of Summit Therapeutics Inc. for potential breaches of fiduciary duties and self-dealing, which could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to seek a free consultation to explore their rights. This investigation raises concerns about management integrity and investor protection at Summit Therapeutics.
